Atara Biotherapeutics Inc ATRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ATRA is a good fit for your portfolio.
News
-
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
-
Atara Biotherapeutics Gets FDA Clearance for ATA3219 IND Application
-
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
-
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
-
Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
-
Atara Biotherapeutics to Submit New FDA Biologics License Application in 2Q
Trading Information
- Previous Close Price
- $0.72
- Day Range
- $0.69–0.74
- 52-Week Range
- $0.20–3.02
- Bid/Ask
- $0.69 / $0.71
- Market Cap
- $85.31 Mil
- Volume/Avg
- 697,941 / 2.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8.83
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 225
- Website
- https://www.atarabio.com
Comparables
Valuation
|
Metric
|
ATRA
|
CELC
|
EQRX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 3.15 | 0.97 |
Price/Sales | 8.83 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ATRA
|
CELC
|
EQRX
|
|---|---|---|---|
Quick Ratio | 0.60 | 12.78 | 18.43 |
Current Ratio | 0.72 | 13.43 | 18.78 |
Interest Coverage | −52.27 | −12.43 | — |
Quick Ratio
ATRA
CELC
EQRX
Profitability
|
Metric
|
ATRA
|
CELC
|
EQRX
|
|---|---|---|---|
Return on Assets (Normalized) | −93.91% | −35.57% | −15.72% |
Return on Equity (Normalized) | −2,452.50% | −49.08% | −16.71% |
Return on Invested Capital (Normalized) | −333.87% | −39.21% | −21.31% |
Return on Assets
ATRA
CELC
EQRX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mdbllszrm | Zhxyv | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lrbtwlbm | Jmyfpk | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ctgyfpvn | Mfqxqfv | $99.5 Bil | |
MRNA
| Moderna Inc | Jqhmvcy | Mxr | $38.8 Bil | |
ARGX
| argenx SE ADR | Ghvlmdqz | Qdn | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Xtssfjzj | Qpc | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mvzsgsy | Vxfdly | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Svbmfqhr | Wybgcx | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gxcfcgjkj | Ggcbmh | $12.5 Bil | |
INCY
| Incyte Corp | Qtvznlth | Lqnvxr | $11.6 Bil |